AML Blood Test – A new method for the early detection and prognosis of acute myeloid leukemia
Diagnosing leukemia, especially acute myeloid leukemia (AML), is hindered due to the unspecific symptoms of the disease. Unfortunately misdiagnoses and mistreatments with antiviral or antibiotic medicine lead to a loss of precious time in fighting against this type of cancer.
Scientists from the University of Bonn tackled this challenge by developing a blood test. This test is based on one of the most advanced approaches of gene expression profiling: gene signatures. By adaptive learning and simulation the new blood test for acute myeloid leukemia (AML-BT) was generated. With an “RNA-fingerprint”, the analysis of the different indicator RNAs – showing a decreased or increased expression rate as indication for AML – can be conducted and used for a reliable diagnosis.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Properties of new materials for microchips
… can now be measured well. Reseachers of Delft University of Technology demonstrated measuring performance properties of ultrathin silicon membranes. Making ever smaller and more powerful chips requires new ultrathin…
Floating solar’s potential
… to support sustainable development by addressing climate, water, and energy goals holistically. A new study published this week in Nature Energy raises the potential for floating solar photovoltaics (FPV)…
Skyrmions move at record speeds
… a step towards the computing of the future. An international research team led by scientists from the CNRS1 has discovered that the magnetic nanobubbles2 known as skyrmions can be…
